{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:26:24Z","timestamp":1794457584629,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102213","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:41:26Z","timestamp":1789666886000},"page":"102213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report"],"prefix":"10.1016","volume":"67","author":[{"given":"Myrtille","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojgan","family":"Devouassoux-Shisheboran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Descargues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Gertych","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionela","family":"Caraivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"P\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.gore.2026.102213_bb0005","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1136\/ijgc-2020-001771","article-title":"Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget\u2019s disease of the vulva","volume":"30","author":"Bartoletti","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.gore.2026.102213_bb0010","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ygyno.2013.02.029","article-title":"Primary extramammary Paget\u2019s disease of the vulva: the clinicopathological features and treatment outcomes in a series of 43 patients","volume":"129","author":"Cai","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"12","key":"10.1016\/j.gore.2026.102213_bb0015","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gore.2026.102213_bb0020","article-title":"Metastatic extramammary Paget\u2019s disease: pathogenesis and novel therapeutic approach","volume":"8","author":"Fukuda","year":"2018","journal-title":"Front. Oncol."},{"issue":"0","key":"10.1016\/j.gore.2026.102213_bb0025","article-title":"HER2-directed therapy in metastatic vulvar empd\u2014a report of two cases and narrative review","volume":"10","author":"Gorecki","year":"2026","journal-title":"AME Case Reports."},{"issue":"3","key":"10.1016\/j.gore.2026.102213_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000333002","article-title":"A case of metastatic extramammary Paget\u2019s disease responding to trastuzumab plus paclitaxel combination therapy","volume":"3","author":"Hanawa","year":"2011","journal-title":"Case Rep. Dermatol."},{"issue":"12","key":"10.1016\/j.gore.2026.102213_bb0035","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.gore.2026.102213_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00204","article-title":"Case of metastatic extramammary Paget disease of the vulva treated successfully with trastuzumab emtansine","volume":"2","author":"Hsieh","year":"2018","journal-title":"JCO Precis. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102213_bb0045","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.3390\/curroncol28040260","article-title":"Extramammary Paget\u2019s disease: diagnosis, pathogenesis, and treatment with focus on recent developments","volume":"28","author":"Ishizuki","year":"2021","journal-title":"Curr. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102213_bb0050","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2007.12.014","article-title":"HER-2\/neu targeting for recurrent vulvar Paget\u2019s disease: a case report and literature review","volume":"111","author":"Karam","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2026.102213_bb0055","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jamaoncol.2021.7148","article-title":"Evidence-based clinical practice guidelines for extramammary Paget disease","volume":"8","author":"Kibbi","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102213_bb0060","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-mutant non\u2013small-cell lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.gore.2026.102213_bb0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2013.12.008","article-title":"Treatment of extramammary Paget disease of the vulva with imiquimod: a retrospective, multicenter study by the German colposcopy network","volume":"70","author":"Luyten","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.gore.2026.102213_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102213_bb0075","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ygyno.2019.11.009","article-title":"Extramammary Paget disease of the vulva: management and prognosis","volume":"157","author":"Nasioudis","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102213_bb0080","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11912-023-01434-0","article-title":"Extramammary Paget disease: a therapeutic challenge, for a rare entity","volume":"25","author":"P\u00e9rez","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.gore.2026.102213_bb0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1056\/NEJMoa2503119","article-title":"Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer","volume":"393","author":"Shitara","year":"2025","journal-title":"New England Journal of Medicine."},{"issue":"4","key":"10.1016\/j.gore.2026.102213_bb0090","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.gore.2026.102213_bb0095","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/bjd.12249","article-title":"Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease","volume":"168","author":"Tanaka","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.gore.2026.102213_bb0100","article-title":"Dramatic clinical response of relapsed metastatic extramammary Paget\u2019s disease to trastuzumab monotherapy","volume":"2012","author":"Wakabayashi","year":"2012","journal-title":"Case Rep. Dermatol. Med."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T04:16:52Z","timestamp":1794457012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"alternative-id":["S2352578926001931"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102213","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dramatic response to trastuzumab-deruxtecan in metastatic HER2-overexpressing vulvar extramammary Paget's disease: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102213"}}